medline.ch Onkologie Urologische Tumoren

	Re: Effect of [68Ga]Ga-PSMA-11 PET-CT in the Diagnosis of Prostate Cancer in Men with Equivocal or Clinically High-risk Non-suspicious Findings in Multiparametric MRI (PRIMARY2): A Multicentre, Non-inferiority, Phase 3, Randomised Controlled Trial. Eur Urol Urso L, Giannarini G, Girometti R, Crestani A, Bauckneht M. PMID: 42463362 [PubMed - as supplied by publisher]
	Abiraterone or Enzalutamide for Patients With Metastatic Castration-Sensitive Prostate Cancer: A Nationwide Veterans Affairs Study. JCO Clin Cancer Inform La J, Wang L, Corrigan JK, Lang D, Do NV, Brophy MT, Fillmore NR, Paller CJ. PMID: 42462188 [PubMed - in process]
	Advanced Prostate Cancer: AUA/SUO Guideline Amendment (2026). Part II: Evaluation and Management of Metastatic Castration-Resistant Prostate Cancer. J Urol Scarpato KR, Cookson MS, Dreicer R, Sayan M, Yu A, D'Anci KE, Pak LJ, Kirkby E. PMID: 42462145 [PubMed - as supplied by publisher]
	Advanced Prostate Cancer: AUA/SUO Guideline Amendment (2026) Part I: Evaluation and Treatment of Biochemically Recurrent (Following Exhaustion of Local Therapy) and Metastatic Hormone-Sensitive Prostate Cancer. J Urol Scarpato KR, Cookson MS, Dreicer R, Sayan M, Yu A, D'Anci KE, Pak LJ, Kirkby E. PMID: 42462144 [PubMed - as supplied by publisher]
	Imaging of Complications after Prostate Interventions. Radiographics Thompson CP, Takahashi H, Broski SM, Froemming AT, Takahashi N, Woodrum DA, Andrews JR, Kawashima A. PMID: 42461755 [PubMed - indexed for MEDLINE]
	Sex differences in the prognostic value of body mass index after curative nephrectomy for high-risk renal cell carcinoma: a multicenter cohort study. Int J Clin Oncol Koterazawa S, Sumiyoshi T, Shibasaki N, Yamasaki T, Ito N, Segawa T, Inoue K, Kanamaru S, Yoshida T, Okubo K, Sugino Y, Kanno T, Masuda N, Ueda M, Koike S, Hoshiyama A, Araki H, Maekawa K, Takuma T, Yamane T, Kita Y, Goto T, Kobayashi T, Masui K, Daimonji Clinical Application Database Group. PMID: 42461516 [PubMed - as supplied by publisher]
	The training paradox in oncosexuality: a multinational survey on clinician attitudes, barriers, and sexual health communication in geriatric prostate cancer care. World J Urol Loganadane G, Motta M, Lester-Coll NH, Lock M, Colin G, Caravatta L, Debbi K, Lara PC, Espíndola Sandoval M, Basu T, Sangalli C, Goyal S, Abd Elbadee OM, Pasinetti N, Vinh-Hung V, Luigi Banna G, Panades M, D'Andrea M, Osti MF, Nguyen NP. PMID: 42461282 [PubMed - indexed for MEDLINE]
	A Novel 7 Sialylation-Related LncRNA Signature as a Prognostic Biomarker in Clear Cell Renal Cell Carcinoma. Curr Med Chem Huang W, Fan C, Li Y, Shu W, Zheng J, Li Y. PMID: 42460535 [PubMed - as supplied by publisher]
	High-sensitivity Raman spectroscopy for prostate cancer detection and tissue extraction guidance. Biomed Opt Express Dooley MJ, Li H, Low I, Christie ML, Pokorny MR, Araquel-Lacamiento A, Porter A, Zargar-Shoshtari K, Aguergaray C. PMID: 42460332 [PubMed]
	Clinical efficacy analysis of acupuncture combined with anti-tumor necrosis factor treatment for spleen and kidney yang deficiency type ulcerative colitis. Front Med (Lausanne) Qin P, Luo Y, Yao Y, Zhu N, Yi W. PMID: 42460073 [PubMed]
	MicroRNA-based diagnosis and therapy in prostate cancer. 3 Biotech Nguyen TA, Le TT, Duong KT, Nguyen AH, Quang MT. PMID: 42459410 [PubMed]
	Androgen receptor signaling organizes ferroptosis escape in castration-resistant prostate cancer: a threshold-based model for therapeutic timing. Front Oncol Wang C, Lv J, Wu J, Wang S, Song S. PMID: 42459323 [PubMed]
	Identification of key genes potentially associated with bladder cancer development by common plasticizers: an integrated transcriptomics and network toxicology study. Front Oncol Zhang Q, Xu K, Chen Z, Li Z, Zhao D. PMID: 42459315 [PubMed]
	Effects of Nicotine on Urinary Bladder Carcinogenesis. Pathol Int Suzuki S, Cohen SM. PMID: 42458916 [PubMed - indexed for MEDLINE]
	External validation of the P-Score in the prospective, pre-biopsy DEPROMP cohort: integrated mpMRI and PSMA PET/CT risk stratification for prostate cancer detection. Eur J Nucl Med Mol Imaging Schmidt CJ, Gaertner FC, Kreppel B, Essler M, Luetkens JA, Attenberger U, Anspach M, Ohlmann CH, Bernhardt M, Kristiansen G, Hauser S, Ellinger J, Ritter M, Krausewitz P. PMID: 42458057 [PubMed - as supplied by publisher]
	Long-term outcomes of real-time TRUS-guided HDR brachytherapy monotherapy for low and favorable intermediate-risk prostate cancer and predictive value of PSA nadir. Brachytherapy Gaztañaga M, Escribano C, Montero B, de Areba J, Martínez DF, Galante I, Serrano-Garcia I, Vázquez MG. PMID: 42457607 [PubMed - as supplied by publisher]
	MR Imaging of the Upper Urinary Tract: Techniques, Diagnostic Performance, and Imaging Biomarkers. Magn Reson Med Sci Nakamoto A, Ota T, Fukui H, Honda T, Kiso K, Kaketaka K, Tanigaki T, Yoshidome E, Ding F, Hirooka R, Onishi H, Hori M, Tomiyama N. PMID: 42457566 [PubMed - indexed for MEDLINE]
	ARALU - Phase 2, Open-label, Randomized Study to Investigate Safety and Efficacy of Pluvicto Therapy in Patients with Metastatic Hormone-sensitive Prostate Cancer in Addition to Standard of Care Treatment with Nubeqa and ADT. Eur Urol Focus Franz J, Brumberg J, Mix M, Meyer PT, Herrmann K, Gratzke C, Sigle A. PMID: 42457482 [PubMed - as supplied by publisher]
	Novel BCG Combination or Modified BCG Regimens in BCG-NaÃ¯ve High-risk Non-muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis. Eur Urol Focus Pattou M, Rouprêt M, Kamat A, Boorjian SA, Gontero P, Shariat SF, D'Andrea D. PMID: 42457481 [PubMed - as supplied by publisher]
	MicroRNAs in Penile Cancer: A Systematic Review of Diagnostic, Prognostic, and Mechanistic Evidence. Eur Urol Focus Zhang X, Rahman F, Kelly JD, Alnajjar HM, Muneer A, Pang KH. PMID: 42457479 [PubMed - as supplied by publisher]

Artikel 1 - 20 / 180097

Seite 1 von 9005

Suchbegriffe

Benutzen Sie englische Suchbegriffe für Ihre Suche in medline.ch.

Übersetzungsproblem?

mehr >>



		Zeitfenster

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Datenschutzerklärung / Privacy Policy \| Werbung